Abstract
18F-FDG-PET/CT is becoming the imaging modality of choice in staging Hodgkin's and high-grade non-Hodgkin's lymphoma, particularly in defining extranodal disease.Assessment of early response after chemotherapy using 18FDG-PET/CT can provide prognostic information, identifying patients who may relapse within 2 years.Residual mass assessment with 18F-FDG-PET/CT has led to the development of more tailor-made treatment strategies.At present, it is unclear if the additional information provided by 18F-FDG-PET/CT translates into better outcomes. The introduction of metabolic imaging with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) has had a major impact on the management of lymphoma. In Hodgkin's and high-grade non-Hodgkin's lymphomas in particular, 18F-FDG-PET/CT has been shown to be more accurate than conventional CT in radiological staging. It can define malignant lesions in structures that appear normal upon anatomical imaging. 18F-FDG-PET/CT is far superior to o...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
